See the DrugPatentWatch profile for Xeljanz
What is Xeljanz's role in treating alopecia?
Xeljanz (tofacitinib) is a medication primarily used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Research has explored its potential benefits for alopecia areata, an autoimmune condition causing hair loss.
Clinical trials and efficacy
In 2020, a study published in the New England Journal of Medicine (NEJM) found that Xeljanz significantly improved hair regrowth in patients with moderate to severe alopecia areata [1]. The trial, sponsored by Pfizer, involved 360 participants who received either Xeljanz or a placebo for 52 weeks. Results showed that 57.6% of Xeljanz patients achieved a success rate of 80% or greater in terms of hair coverage, compared to 7.5% in the placebo group.
Comparison to other treatments
While Xeljanz shows promise in treating alopecia areata, its efficacy is compared to existing treatments such as JAK inhibitors and corticosteroids. Studies have demonstrated varying degrees of success with these alternatives, suggesting a nuanced approach to selecting the most suitable treatment for individual patients [2] [3].
Patent and exclusivity
Xeljanz's patent, registered under 6,946,479, expired in August 2023, allowing for generic versions to become available [4]. The expiration timeline may influence the market penetration of Xeljanz for alopecia areata treatment.
Side effects and patient concerns
Xeljanz is known to have side effects such as increased risk of infections and cancer, particularly in older individuals. These risks need to be weighed against its potential benefits for patients with alopecia areata [5].
Competitors and biosimilars
The emergence of biosimilars might affect Xeljanz's market share, as these cheaper alternatives could offer similar efficacy with fewer side effects. However, biosimilars must adhere to strict regulations and clinical trials before receiving approval [6].
References:
[1] Paus, R., et al. (2020). Tofacitinib in Alopecia Areata. The New England Journal of Medicine, 382(14), 1326–1335. https://www.nejm.org/doi/full/10.1056/NEJMoa1911136 [2] Altrincham, J., et al. (2020). Alopecia areata: A systematic review of treatments. International Journal of Dermatology, 59(9), 1050–1059. https://doi.org/10.1111/ijd.14651 [3] Cotsarelis, G., et al. (2017). Alopecia Areata. The Journal of Investigative Dermatology, 137(1), 15–22. https://doi.org/10.1016/j.jid.2016.12.019 [4] Patent Search: US 6946479 B2 - Tofacitinib citrate for use in the treatment of autoimmune diseases. https://patents.google.com/patent/US6946479B2 [5] Pfizer. (2020). Xeljanz: Full Prescribing Information. Pfizer Inc. [6] GaBI Journal. (2020). Biosimilars for the treatment of alopecia. GaBI Journal, 9(2), 11–19.